Aardvark Therapeutics falls after pausing late-stage rare disease trial
27/02/2026 22:13
** Shares of drug developer Aardvark Therapeutics AARD.O fall 47.2% to $6.58 aftermarkets
** Co says it is voluntarily pausing its late-stage trial testing its experimental treatment for a type of rare genetic disease
** Says decision was made after it found heart-related side effects during safety monitoring in a healthy volunteer study in patients receiving higher‑than‑planned doses of the treatment
** Says no longer anticipates announcing topline data from the trial in the third quarter of 2026
** Stock has fallen 12.6% since its Nasdaq debut last year
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))